Pfizer Inc. (PFE) Shares Sold by Andra AP fonden
Andra AP fonden lowered its holdings in Pfizer Inc. (NYSE:PFE) by 0.5% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 661,900 shares of the biopharmaceutical company’s stock after selling 3,025 shares during the period. Pfizer makes up 0.6% of Andra AP fonden’s portfolio, making the stock its 20th biggest position. Andra AP fonden’s holdings in Pfizer were worth $22,233,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also added to or reduced their stakes in PFE. Altfest L J & Co. Inc. raised its holdings in shares of Pfizer by 67.0% during the second quarter. Altfest L J & Co. Inc. now owns 107,278 shares of the biopharmaceutical company’s stock worth $3,603,000 after acquiring an additional 43,024 shares in the last quarter. HL Financial Services LLC raised its holdings in shares of Pfizer by 1.1% during the second quarter. HL Financial Services LLC now owns 3,222,985 shares of the biopharmaceutical company’s stock worth $108,260,000 after acquiring an additional 35,744 shares in the last quarter. Sphera Funds Management LTD. purchased a new stake in shares of Pfizer during the first quarter worth $13,342,000. Searle & CO. raised its holdings in shares of Pfizer by 92.7% during the first quarter. Searle & CO. now owns 80,052 shares of the biopharmaceutical company’s stock worth $2,739,000 after acquiring an additional 38,500 shares in the last quarter. Finally, Hartford Financial Management Inc. raised its holdings in shares of Pfizer by 10.8% during the second quarter. Hartford Financial Management Inc. now owns 8,538 shares of the biopharmaceutical company’s stock worth $286,000 after acquiring an additional 835 shares in the last quarter. Institutional investors own 69.89% of the company’s stock.
Several analysts recently issued reports on PFE shares. Cowen set a $43.00 price objective on Pfizer and gave the stock a “buy” rating in a report on Monday, August 14th. Berenberg Bank reissued a “hold” rating and set a $36.00 target price (down from $39.00) on shares of Pfizer in a research report on Tuesday, August 15th. Jefferies Group reissued a “hold” rating and set a $35.00 target price on shares of Pfizer in a research report on Friday, August 18th. BMO Capital Markets reissued a “buy” rating and set a $37.00 target price on shares of Pfizer in a research report on Wednesday, September 6th. Finally, Vetr downgraded shares of Pfizer from a “buy” rating to a “hold” rating and set a $35.71 target price on the stock. in a research report on Wednesday, September 13th. Two equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and thirteen have given a buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $38.66.
In other news, insider Alexander R. Mackenzie sold 14,700 shares of the firm’s stock in a transaction dated Wednesday, November 1st. The stock was sold at an average price of $35.30, for a total value of $518,910.00. Following the sale, the insider now directly owns 117,432 shares of the company’s stock, valued at $4,145,349.60. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Alexander R. Mackenzie sold 7,350 shares of the firm’s stock in a transaction dated Monday, October 2nd. The shares were sold at an average price of $35.65, for a total value of $262,027.50. Following the completion of the sale, the executive vice president now directly owns 117,432 shares in the company, valued at $4,186,450.80. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 60,280 shares of company stock worth $2,118,988. 0.06% of the stock is currently owned by company insiders.
Shares of Pfizer Inc. (NYSE PFE) traded down $0.21 during trading hours on Tuesday, hitting $35.86. The stock had a trading volume of 5,396,030 shares, compared to its average volume of 19,979,412. The firm has a market capitalization of $216,671.69, a P/E ratio of 14.54, a P/E/G ratio of 2.57 and a beta of 1.01. Pfizer Inc. has a 12 month low of $30.51 and a 12 month high of $36.78. The company has a current ratio of 1.43, a quick ratio of 1.15 and a debt-to-equity ratio of 0.56.
Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.67 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.65 by $0.02. The company had revenue of $13.17 billion for the quarter, compared to the consensus estimate of $13.17 billion. Pfizer had a return on equity of 25.41% and a net margin of 18.69%. The firm’s revenue was up .9% compared to the same quarter last year. During the same period last year, the business posted $0.61 earnings per share. research analysts predict that Pfizer Inc. will post 2.59 EPS for the current fiscal year.
The firm also recently declared a quarterly dividend, which was paid on Friday, December 1st. Stockholders of record on Friday, November 10th were given a $0.32 dividend. This represents a $1.28 annualized dividend and a dividend yield of 3.57%. The ex-dividend date was Thursday, November 9th. Pfizer’s dividend payout ratio is currently 79.01%.
Pfizer Company Profile
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.